Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
orelabrutinib + rituximab + lenalidomide
- Development stage
- Unknown
- Lead developer
- InnoCare Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a triple combination therapy consisting of orelabrutinib (a BTK inhibitor), rituximab (an anti-CD20 monoclonal antibody), and lenalidomide (an immunomodulatory agent). While the rituximab + lenalidomide combination is well-established for treating relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), particularly follicular lymphoma (FL) and marginal zone lymphoma (MZL), the addition of orelabrutinib to this regimen is not documented in the provided search results. The rituximab + lenalidomide combination has shown significant efficacy in clinical trials and real-world settings for relapsed/refractory iNHL, with high response rates and improved progression-free survival compared to rituximab monotherapy.
- Brand names
- RituxanRevlimid
- Other names
- OLROLR regimen
02
Targets
Beyond the preview
Go deeper on orelabrutinib + rituximab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on orelabrutinib + rituximab + lenalidomide.